renal-cell carcinoma (advanced)  

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

All mechanism

not classified
Disruptor-1BNC105P + everolimuseverolimus -
Motzer, 2015 ongoing lenvatinibeverolimusNCT01136733 ongoing
apitolisib
Powles, 2014apitolisibeverolimus -
axitinib
AXIS (Rini), 2011axitinibsorafenibNCT00678392suggesting
Qin, 2012axitinibsorafenib -
bevacizumab
CALGB 90206, 2010bevacizumab plus interferon alfainterferon alphasuggesting
AVOREN, 2007bevacizumab plus interferon alfainterferon alphasuggesting
Yang, 2003bevacizumabplaceboExploratory -
cabozantinib
METEOR, 2015cabozantinibeverolimus after VEGFR-targeted therapy failure 2nd line NCT01865747Risk of bias suggesting
CABOSUN, 2017cabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk 1st line NCT01835158Exploratory suggesting
dovitinib
GOLDdovitinibsorafenibNCT01223027Risk of bias negative
everolimus
RECORD-1, 2008everolimusplaceboNCT00410124suggesting
RECORD 3, 2014everolimussunitinibNCT00903175 -
nivolumab
CheckMate 025, 2015nivolumabeverolimusNCT01668784suggesting
pazopanib
VEG105192, 2010pazopanibplaceboNCT00334282suggesting
Sternberg, 2010pazopanibplaceboLow risk of bias suggesting
COMPARZ, 2013pazopanibsunitinibNCT00720941negative
sorafenib
Escudier, 2009sorafenibinterferon alphaExploratory negative
TARGET, 2007sorafenibplaceboNCT00073307Low risk of bias suggesting
Ratain, 2006sorafenibplaceboExploratory -
sunitinib
Motzer, 2007sunitinibinterferon alphaNCT00083889suggesting
SWITCHsunitinibsorafenibNCT00732914 -
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007temsirolimusinterferon alphaNCT00065468suggesting
INTORSECT, 2014temsirolimussorafenibNCT00474786negative
tivozanib
TIVO-1, 2013tivozanibsorafenibNCT01030783suggesting

angiogenesis inhibitors

bevacizumab
CALGB 90206, 2010bevacizumab plus interferon alfainterferon alphasuggesting
AVOREN, 2007bevacizumab plus interferon alfainterferon alphasuggesting
Yang, 2003bevacizumabplaceboExploratory -

immune checkpoint inhibition

atezolizumab
NCT02420821 ongoing atezolizumab + bevacizumab1LNCT02420821Risk of bias ongoing
avelumab
JAVELIN Renal 101 ongoing avelumab + axitinibsunitinib1L, PDL1 positiveNCT02684006Risk of bias ongoing
nivolumab
Chekmate 025 (Motzer), 2015nivolumabeverolimus2LNCT01668784Risk of bias suggesting
CheckMate-214, 2017nivolumab + ipilimumabsunitinib1LNCT02231749Risk of bias suggesting
pembrolizumab
KEYNOTE-426 ongoing pembrolizumab + axitinibsunitinibNCT02853331 ongoing

Immunotherapy

nivolumab
CheckMate 025, 2015nivolumabeverolimusNCT01668784suggesting
CheckMate 214 ongoing nivolumab+ ipilimumabsunitinibNCT02231749 ongoing

mTOR inhibitor

everolimus
RECORD-1, 2008everolimusplaceboNCT00410124suggesting
RECORD 3, 2014everolimussunitinibNCT00903175 -
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007temsirolimusinterferon alphaNCT00065468suggesting
INTORSECT, 2014temsirolimussorafenibNCT00474786negative

multi target TKI

not classified
Disruptor-1BNC105P + everolimuseverolimus -
Motzer, 2015 ongoing lenvatinibeverolimusNCT01136733 ongoing
apitolisib
Powles, 2014apitolisibeverolimus -
axitinib
AXIS (Rini), 2011axitinibsorafenibNCT00678392suggesting
Qin, 2012axitinibsorafenib -
cabozantinib
METEOR, 2015cabozantinibeverolimus after VEGFR-targeted therapy failure 2nd line NCT01865747Risk of bias suggesting
CABOSUN, 2017cabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk 1st line NCT01835158Exploratory suggesting
dovitinib
GOLDdovitinibsorafenibNCT01223027Risk of bias negative
pazopanib
Sternberg, 2010pazopanibplaceboLow risk of bias suggesting
VEG105192, 2010pazopanibplaceboNCT00334282suggesting
COMPARZ, 2013pazopanibsunitinibNCT00720941negative
sorafenib
Escudier, 2009sorafenibinterferon alphaExploratory negative
TARGET, 2007sorafenibplaceboNCT00073307Low risk of bias suggesting
Ratain, 2006sorafenibplaceboExploratory -
sunitinib
Motzer, 2007sunitinibinterferon alphaNCT00083889suggesting
SWITCHsunitinibsorafenibNCT00732914 -
tivozanib
TIVO-1, 2013tivozanibsorafenibNCT01030783suggesting